Study of alemtuzumab (Campath-1H) monoclonal antibody in patients with relapsed and resistant classical Hodgkin's disease.

Trial Profile

Study of alemtuzumab (Campath-1H) monoclonal antibody in patients with relapsed and resistant classical Hodgkin's disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2009 Primary endpoint identified as response rate as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 10 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top